CD44S-hyaluronan interactions protect cells resulting from EMT against anoikis

Matrix Biology

Volumn 48, Issue , 2015, Pages 55-65

  Cieply, Benjamin ^a,b   Koontz, Colton ^a   Frisch, Steven M ^a,b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anoikis; Apoptosis; CD44; Epithelial mesenchymal transition; Hyaluronan

Indexed keywords

CD44E ANTIGEN; CD44S ANTIGEN; DOXYCYCLINE; HERMES ANTIGEN; HYALURONIC ACID; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; GLUCURONOSYLTRANSFERASE; HAS2 PROTEIN, HUMAN; PROTEIN BINDING;

ANOIKIS; APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOSKELETON; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; CELL PROLIFERATION; CHEMISTRY; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANOIKIS; ANTIGENS, CD44; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HUMANS; HYALURONIC ACID; PROTEIN BINDING; SIGNAL TRANSDUCTION;

EID: 84947866671     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2015.04.010     Document Type: Article

References (37)

1. Frisch S.M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994, 124:619-626.
2. Brabletz T. EMT and MET in metastasis: where are the cancer stem cells?. Cancer Cell 2013, 22:699-701.
3. Creighton C.J., Chang J.C., Rosen J.M. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:253-260.
4. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009, 106:13820-13825.
5. Dave B., Mittal V., Tan N.M., Chang J.C. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 2012, 14:202.
6. Frisch S.M., Schaller M., Cieply B. Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J Cell Sci 2013, 126:21-29.
7. Zoller M. CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. J Mol Med (Berl) 1995, 73:425-438.
8. Ponta H., Sherman L., Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003, 4:33-45.
9. Bajorath J., Greenfield B., Munro S.B., Day A.J., Aruffo A. Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J Biol Chem 1998, 273:338-343.
10. Bennett K.L., Modrell B., Greenfield B., Bartolazzi A., Stamenkovic I., Peach R., et al. Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol 1995, 131:1623-1633.
11. Wielenga V.J., Smits R., Korinek V., Smit L., Kielman M., Fodde R., et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 1999, 154:515-523.
12. Godar S., Ince T.A., Bell G.W., Feldser D., Donaher J.L., Bergh J., et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008, 134:62-73.
13. Warzecha C.C., Jiang P., Amirikian K., Dittmar K.A., Lu H., Shen S., et al. An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J 2010, 29:3286-3300.
14. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat Rev Cancer 2011, 11:254-267.
15. Toole B.P., Slomiany M.G. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol 2008, 18:244-250.
16. Toole B.P., Slomiany M.G. Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat 2008, 11:110-121.
17. Marangoni E., Lecomte N., Durand L., de Pinieux G., Decaudin D., Chomienne C., et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer 2009, 100:918-922.
18. Xu X.M., Chen Y., Chen J., Yang S., Gao F., Underhill C.B., et al. A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis. Cancer Res 2003, 63:5685-5690.
19. Louderbough J.M., Schroeder J.A. Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res 2011, 9:1573-1586.
20. Keysar S.B., Jimeno A. More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther 2010, 9:2450-2457.
21. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
22. Cieply B., Riley P.t., Pifer P.M., Widmeyer J., Addison J.B., Ivanov A.V., et al. Suppression of the epithelial-mesenchymal transition by grainyhead-like-2. Cancer Res 2012, 72:2440-2453.
23. Debnath J., Muthuswamy S.K., Brugge J.S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268.
24. Cieply B., Farris J., Denvir J., Ford H.L., Frisch S.M. Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2. Cancer Res 2013, 73:6299-6309.
25. van Weering D.H., Baas P.D., Bos J.L. A PCR-based method for the analysis of human CD44 splice products. PCR Methods Appl 1993, 3:100-106.
26. Melrose J., Tammi M., Smith S. Visualisation of hyaluronan and hyaluronan-binding proteins within ovine vertebral cartilages using biotinylated aggrecan G1-link complex and biotinylated hyaluronan oligosaccharides. Histochem Cell Biol 2002, 117:327-333.
27. Kumar S., Park S.H., Cieply B., Schupp J., Killiam E., Zhang F., et al. A pathway for the control of anoikis sensitivity by E-cadherin and epithelial-to-mesenchymal transition. Mol Cell Biol 2011, 31:4036-4051.
28. Ruffell B., Johnson P. Hyaluronan induces cell death in activated T cells through CD44. J Immunol 2008, 181:7044-7054.
29. Sansonetti A., Bourcier S., Durand L., Chomienne C., Smadja-Joffe F., Robert-Lezenes J. CD44 activation enhances acute monoblastic leukemia cell survival via Mcl-1 upregulation. Leuk Res 2012, 36:358-362.
30. Legg J.W., Lewis C.A., Parsons M., Ng T., Isacke C.M. A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nat Cell Biol 2002, 4:399-407.
31. Porsch H., Bernert B., Mehic M., Theocharis A.D., Heldin C.H., Heldin P. Efficient TGFbeta-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene 2013, 32:4355-4365.
32. Petrey A.C., de la Motte C.A. Hyaluronan, a crucial regulator of inflammation. Front Immunol 2014, 5:101.
33. Lee J.L., Wang M.J., Chen J.Y. Acetylation and activation of STAT3 mediated by nuclear translocation of CD44. J Cell Biol 2009, 185:949-957.
34. De Falco V., Tamburrino A., Ventre S., Castellone M.D., Malek M., Manie S.N., et al. CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells. Cancer Res 2012, 72:1449-1458.
35. Takahashi E., Nagano O., Ishimoto T., Yae T., Suzuki Y., Shinoda T., et al. Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem 2010, 285:4060-4073.
36. Brown R.L., Reinke L.M., Damerow M.S., Perez D., Chodosh L.A., Yang J., Cheng C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011, 121:1064-1074.
37. Naor D., Wallach-Dayan S.B., Zahalka M.A., Sionov R.V. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008, 18:260-267.